Seattle startup Integrated Diagnostics, or Indi, picked up $47.3 million in equity and debt financing, money it'll use to expand the market for its lung nodule-diagnosing test. Under the financing deal, Indi raised $30.3 million in Series B money from investors including Baird Capital, InterWest Partners and the Wellcome Trust, and separately secured a $17 million debt facility from Life Sciences Alternative Funding. Now, the company is planning to amp up marketing for its Xpresys test, designed to cheaply determine whether lung growths are benign, ruling out costlier biopsies and saving money for patients and providers. Article